NW16

NW16 is an orally active inhibitor for STAT3 with Kd of 11.0 μM. NW16 arrests the cell cycle at S phase, induces apoptosis in HCT116, and inhibits the proliferation of cancer cell HCT116, A549, and B16 with IC50s of 0.28, 1.22, and 9.86 μM, respectively. NW16 induces the production of ROS, inhibits the PI3K/AKT signaling pathway, and thus exhibits antitumor efficacy in mouse model[1].

Product Specifications

UNSPSC

12352005

Target

Apoptosis; Reactive Oxygen Species (ROS) ; STAT

Type

Reference compound

Related Pathways

Apoptosis; Immunology/Inflammation; JAK/STAT Signaling; Metabolic Enzyme/Protease; NF-κB; Stem Cell/Wnt

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/nw16.html

Smiles

N#C/C(C(NCCO)=O)=C\C1=CC2=C(O1)C(C3=CC=CC=C3C2=O)=O

Molecular Formula

C18H12N2O5

Molecular Weight

336.30

References & Citations

[1]Jiang W, et al., Design, synthesis, and biological evaluation of novel (E) -2-cyano-3- (4,9-dioxo-4,9-dihydronaphtho[2,3-b]furan-2-yl) derivatives as potent STAT3-targeting anticolorectal cancer agents. Bioorg Chem. 2024 Dec;153:107955.